CLINICAL_TRIALS
trial_result
· 2014-06-18
Clinical Trial Update: 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients [Phase 2]
Summary
Boehringer Ingelheim reported results from a Phase 2 study evaluating three dose levels of BI 10773 in adults with type 2 diabetes over 12 weeks.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2014-06-18